Startup Neumora Therapeutics’ new depression treatment, navacaprant, failed in a Phase 3 clinical trial, showing no significant improvement in depression scores compared to a placebo. Both groups reported a 12.5-point reduction in scores, and the drug did not show a statistically significant improvement in participants’ ability to experience pleasure. This is the first of three Phase 3 studies planned for navacaprant by the company. The disappointing results raise concerns about the effectiveness of the treatment and highlight the challenges faced by startups in developing new therapies for mental health conditions.
Source link
Neumora’s antidepressant stumbles in first Phase 3 trial readout
